sunitinib fmk 37,5 mg tvrdé kapsuly
farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica
sunitinib fmk 25 mg tvrdé kapsuly
farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica
sunitinib fmk 12,5 mg tvrdé kapsuly
farmak international sp. z o.o., poľsko - sunitinib - 44 - cytostatica
sunitinib zentiva 37,5 mg
zentiva, k.s., Česká republika - sunitinib - 44 - cytostatica
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib krka 12,5 mg tvrdé kapsuly
krka, d.d., novo mesto, slovinsko - sunitinib - 44 - cytostatica
klertis 50 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
klertis 25 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
klertis 12,5 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
inlyta
pfizer europe ma eeig - axitinib - karcinóm, obličková bunka - protein kinase inhibítory - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.